Diagnosis of cutaneous T-cell lymphoma by insurance type before and after the Affordable Care Act: a national database study by Ramachandran, Vignesh et al.
UC Davis
Dermatology Online Journal
Title
Diagnosis of cutaneous T-cell lymphoma by insurance type before and after the Affordable 
Care Act: a national database study
Permalink
https://escholarship.org/uc/item/5n4481mk
Journal
Dermatology Online Journal, 25(11)
Authors
Ramachandran, Vignesh
Park, Katherine E
Shah, Jesal R
et al.
Publication Date
2019
License
https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0
eScholarship.org Powered by the California Digital Library
University of California
Volume 25 Number 11| November 2019| 
25(11):4 
 
 
- 1 - 
Dermatology Online Journal  ||  Commentary 
Diagnosis of cutaneous T-cell lymphoma by insurance 
type before and after the Affordable Care Act: a national 
database study 
 
Vignesh Ramachandran1,2 BS, Katherine E Park1,2 BS1,2, Jesal R Shah3 BS BA, Madeleine Duvic2 MD 
Affiliations: 1Baylor College of Medicine, Houston, Texas, USA, 2The University of Texas MD Anderson Cancer Center, 
Houston, Texas, USA, 3Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA 
Corresponding Author: Vignesh Ramachandran, 1 Baylor Plaza, Houston, Texas, 77030, Tel: 512-431-2236, Email: 
vigneshr@bcm.edu 
 
 
Keywords: cutaneous T-cell lymphoma, CTCL, 
Affordable Care Act, ACA, Medicaid, diagnosis, 
population-based, Surveillance Epidemiology and End 
Results Cancer Database, SEER 
 
Introduction 
The introduction of the Patient Protection and 
Affordable Care Act (ACA) in 2010 ushered in the 
most prominent healthcare structural change 
since introduction of Medicare and Medicaid in 
1965. This law was implemented in large part to 
increase the accessibility of health care and 
reduce the uninsured in the age group between 
pediatric and Medicare populations (18-64 years 
old), [1]. Although signed into law in 2010, the 
ACA formally introduced Medicaid expansion 
(allowing eligibility for individuals with household 
incomes up to 138% of the federal poverty line) 
and health insurance exchanges in January 2014 
[2]. The years between 2010 and 2015 saw a 
dramatic decrease from 49 million to 29 million in 
the number of uninsured individuals in the United 
States [3]. 
Health insurance is associated with cancer 
screening, stage at diagnosis, type of treatment 
obtained, and outcomes [4]. Although statistics 
regarding the decreasing uninsured population 
are intriguing, the future of the ACA is uncertain. 
As such, it is necessary to evaluate how this policy 
Abstract 
The Affordable Care Act (ACA) was implemented 
to increase health care access and reduce the 
uninsured in the age group between pediatric and 
Medicare populations (18-64). The association of 
the ACA with insurance type upon diagnosis 
(uninsured, Medicaid, non-Medicaid) has been 
investigated for otolaryngologic, gynecologic, and 
the top five non-skin malignancies. Such studies 
for cutaneous malignancies are lacking. We 
conducted a retrospective analysis of the 
prospective National Cancer Institute’s 
Surveillance, Epidemiology, and End Results 
(SEER) cancer database to assess the impact of the 
ACA on new diagnoses of cutaneous T-cell 
lymphoma (CTCL) by insurance type. Unlike prior 
studies of other malignancies, we did not observe 
significant differences between rate of diagnosis 
of CTCL by insurance type before and after full 
implementation of the ACA in all states, expansion 
states, and non-expansion states. Skin cancers do 
not have screening guidelines and CTCL is an 
uncommon malignancy, both of which may 
contribute to these findings. However, Medicaid-
expansion states were much closer to reducing the 
percentage of newly diagnosed uninsured 
patients with CTCL than non-expansion states. As 
such, it may be prudent to investigate intrinsic 
socioeconomic barriers to care in Medicaid 
patients to improve their access to care to 
decrease the uninsured population and improve 
outcomes. 
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impacts outcomes in those patients most 
influenced by the policy (Medicaid and Medicare-
ineligible adult patients). The association of the 
ACA with insurance type upon diagnosis 
(uninsured, Medicaid, non-Medicaid) has been 
investigated for otolaryngologic, gynecologic, 
and the top five non-skin malignancies [5-7]. Such 
studies for cutaneous malignancies are lacking. 
Cutaneous T-cell lymphoma (CTCL) comprised a 
heterogeneous group of T-cell 
lymphoproliferative disorders affecting the skin 
with mean age of onset in the fifties [8]. Herein, 
we assess the impact of the ACA on new 
diagnoses of CTCL before and after its full 
implementation. 
 
Methods 
We conducted a retrospective analysis of the 
prospective National Cancer Institute’s 
Surveillance, Epidemiology, and End Results 
(SEER) cancer database, which pools data from 18 
registries encompassing approximately 34.6% of 
cancer diagnoses in the United States [9]. 
Institutional board review was waived as SEER-
Medicare data are exempt. Inclusion criteria were: 
patients between age 18-64 years old eligible for 
Medicaid (Medicare insurance data unavailable in 
SEER), CTCLs with prevalence of ≥1%, and cases 
diagnosed from 2007-2015 (years with recorded 
insurance data). Exclusion criteria included: 
lymphoproliferative disorders that may have 
cutaneous involvement (lymphoma cutis), broad 
International Classification of Diseases for 
Oncology-3 (ICD) codes encompassing multiple 
heterogeneous diagnoses, and cases with 
“unknown” insurance designation. International 
Classification of Diseases for Oncology-3 used 
were: 9700/3 (mycosis fungoides), 9701/3 (Sezary 
syndrome), 9708/3 (subcutaneous panniculitis-
like T-cell lymphoma), 9718/3 (primary cutaneous 
anaplastic large cell lymphoma), 9719/3 
(extranodal NK/T-cell lymphoma, nasal type), and 
9726/3 (primary cutaneous gamma-delta T-cell 
lymphoma). A total of 2,900 cases were analyzed. 
Standard mean differences with 95% confidence 
intervals (CI) were calculated for all cases 
diagnosed by insurance type (uninsured, 
Medicaid, non-Medicaid) in the United States 
before (2007-2013) and after full implementation 
of the ACA (2014-2015). This analysis was 
repeated for Medicaid expansion states and non-
expansion states to assess the impact of this 
 
 
Figure 1. Insurance rate trends for patients diagnosed with 
cutaneous T-cell lymphoma in all states (top), Medicaid 
expansion states (middle), and Medicaid non-expansion 
states (bottom). 
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policy on uninsured rates in states which did, or 
did not implement this aspect of the ACA. P values 
<0.05 were deemed significant. 
 
Results 
No significant differences were found between 
rate of diagnosis of CTCL by insurance type before 
and after full implementation of the ACA in all 
states, expansion states, and non-expansion 
states. Prior research, however, shows that 
Medicaid expansion led to decreases in patients 
with uninsured status diagnosed with 
gynecologic, otolaryngologic, and the top five 
non-skin cancers nationally (all states) and in 
states that expanded Medicaid, but not in non-
expansion states [5-7]. In fact, according to a 
study by Soni et al., uninsurance among patients 
with newly diagnosed top-five non-skin cancer 
fell by one-third in the ACA’s first year [7]. 
Specifically, they demonstrated a decrease in the 
percentage of patients without health insurance 
for the following cancers: breast (-25.86%), 
prostate (-29.32%), colorectal (-33.75%), lung and 
bronchial (-32.67%), and thyroid (-32.98%), [7]. 
These results vary greatly from those depicted in 
this study. Results are presented in Figure 1 and 
Table 1. 
Discussion 
Many of the most common malignancies, such as 
colon cancer, gynecologic cancers, and breast 
cancer, have established screening guidelines 
covered under Medicaid, whereas skin cancers 
have no screening recommendations [3, 5]. 
Increased access to primary care facilities may 
facilitate screening for these malignancies. These 
cancers are also relatively well-known to the 
general public compared to CTCL, which is often 
diagnosed by specialists (i.e. dermatology). 
Cutaneous T-cell lymphoma is also less common 
than squamous cell carcinoma of the head and 
neck. Even though the latter has no screening 
guidelines, the sheer volume of malignancies may 
reflect in an appreciable decrease in uninsured 
population as a result of generally improved 
insurance coverage options after implementation 
of the ACA. These factors may lead to the prior 
studies’ findings of ACA reducing the number of 
uninsured patients diagnosed with these cancers, 
a finding not observed in our study. 
Of the numerous health care policies 
implemented as part of the ACA to reduce the 
uninsured rate, Medicaid expansion has been the 
most important [5-7]. In our study, Medicaid-
expansion states were much closer to increasing 
the percentage of new CTCL diagnoses in  
Table 1. Percentages of diagnosed cases of cutaneous T-cell lymphoma in all states (left), Medicaid expansion states (middle), 
and Medicaid non-expansion states (right) before (2007-2013) and after (2014-2015) full implementation of the Affordable 
Care Act. 
 
Insurance 
Status Uninsured Medicaid 
Other 
Insured Uninsured Medicaid 
Other 
Insured Uninsured Medicaid 
Other 
Insured 
Pre-
Expansion 
4.64% 9.04% 86.32% 4.14% 9.32% 86.54% 8.06% 7.48% 84.46% 
Post-
Expansion 
3.28% 11.06% 85.66% 2.36% 10.65% 86.99% 10.10% 9.50% 80.40% 
Difference -1.36% +2.02% -0.66% -1.78% +1.33% +0.45% +2.04% +2.02% -4.06% 
95% 
Confidence 
Interval 
-4.86%-
+2.14% 
-1.70%-
+5.74% 
-6.72%-
+5.40% 
-4.79%- 
+1.23% 
-3.62%- 
+6.28% 
-6.10%-
+7.00% 
-6.28%-
+10.36% 
-7.38%-
+11.41% 
-14.59%-
+6.47% 
P-Value 0.388 0.24 0.322 0.20 0.55 0.88 0.58 0.63 0.39 
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uninsured patients (-1.78%, P=0.20) compared to 
non-expansion states, which had an increased in 
newly diagnosed uninsured patients (+2.04%). 
Medicaid is a surrogate for socioeconomic status. 
For low socioeconomic patients, access to 
insurance may not offset additional hurdles such 
as lack of access to care (and specialty services), 
transportation, cost, education, and loss of 
insurance coverage during workup/treatment 
[10-14]. In an uncommon malignancy like CTCL, 
the impact of socioeconomic status may be 
amplified in patients’ ability to seek specialty care 
for diagnosis and treatment. Furthermore, prior 
investigation shows that outcomes in Medicaid-
insured CTCL patients are worse than privately-
insured patients [15]. Thus, further investigation 
into these factors and addressing them may be 
beneficial in amplifying the positive impact of the 
ACA, expanding its utility for more uncommon 
cancers and improving survival outcomes. 
Limitations of this study include possible data 
entry errors, possible insurance status changes 
during the study period, lack of long-term data, 
and inability to include unknown insurance cases 
and non-specific ICD codes (9702/3 and 9709/3, 
N=2,308). It also does not include patients older 
than 64. However, the ages under investigation 
(18-64) are pertinent in study of the ACA and 
older age groups are beyond the scope of this 
study as such patients are eligible for Medicare, 
an insurance status not tracked in SEER. 
 
Conclusion 
This is a first-of-its-kind study of a dermatologic 
diagnosis, particularly in that we are evaluating 
the ACA’s impact on an uncommon malignancy 
like CTCL. Moving forward, it would be prudent to 
develop policy to address socioeconomic barriers 
to improve access to care and outcomes beyond 
insurance coverage. 
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